Lymphatic Abnormalities clinical trials
The registry lists 42 studies for Lymphatic Abnormalities across more than 10 countries. 17 are recruiting or about to start. 25 of them are mainly about Lymphatic Abnormalities (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23. Counting its narrower condition DiGeorge Syndrome too: 89 studies, 28 open.
Get an email when these change. Save the Lymphatic Abnormalities studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
West China Hospital (3) · University of Aarhus (3) · Boston Children's Hospital (2) · Nanjing Children's Hospital (2) · University of Arkansas (2) · Medical College of Wisconsin (2) · Stanford University (2) · Venthera, Inc., a BridgeBio company (1)
What is being tested here
Drugs under test in Lymphatic Abnormalities studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4, phase 3 first
- Dec 2026Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations · Phase 3 · West China Hospital
- Dec 2026Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age · Protara Therapeutics
- Jan 2027A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations · Murdoch Childrens Research Institute
- Feb 2027Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations · University Hospital, Lille
Who these studies take
Of the 14 Lymphatic Abnormalities studies recruiting now, 6 (43%) set no upper age limit and 5 (36%) stop at 75 or younger. 14 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 14 (100%) | 14 (100%) |
| 18 | 12 (86%) | 12 (86%) |
| 30 | 9 (64%) | 9 (64%) |
| 40 | 9 (64%) | 9 (64%) |
| 50 | 9 (64%) | 9 (64%) |
| 65 | 9 (64%) | 9 (64%) |
| 75 | 9 (64%) | 9 (64%) |
| 85 | 9 (64%) | 9 (64%) |
Across all 42 studies, recruiting or not: 40% stop at 75 or younger and 38% at 65; 83% take children; 2% are for women only and 0% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 42 of 42. search them.
- A Prospective Natural History Study of Lymphatic AnomaliesRecruitingNCT057311411 country
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingNCT05948943Phase 2/312 countries
- A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES SyndromeRecruitingNCT07285005Phase 33 countries
- Lymphatic Anomalies Registry for the Assessment of Outcome DataRecruitingNCT023995271 country
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)RecruitingNCT06789913Phase 29 countries
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeRecruitingNCT05871970Phase 21 country
- Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic MalformationsRecruitingNCT03243019Phase 21 country
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 21 country
- Weekly Sirolimus TherapyRecruitingNCT04861064Phase 21 country
- A Prospective Study on the Treatment of cLM Based on ICG ImagingRecruitingNCT06275022Not applicable1 country
- European Registry Study on Lymphatic InterventionsRecruitingNCT071312931 country
- Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic MalformationsNot yet recruitingNCT07320001Phase 2
- Diagnostic Imaging of Vascular Malformations Using MSOT and ULMNot yet recruitingNCT069942601 country
- Institution of an Italian Registry and Biobank for Biological Sample CollectionRecruitingNCT06892964Not applicable1 country
- Radiofrequency Ablation of Vascular AnomaliesNot yet recruitingNCT06803667Not applicable
- Different Doses of Sirolimus for the Treatment of Cystic Lymphatic MalformationsRecruitingNCT06673290Phase 2/31 country
- Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric PatientsRecruitingNCT06437158Phase 21 country
- Apple Peptide Complex for Post-Surgical and Aesthetic Skin RecoveryCompletedNCT07807085Not applicable1 country
- Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and NeckCompletedNCT07728825Phase 41 country
- Bleomycin Intralesional Injections of Cystic HygromasCompletedNCT07189832Not applicable1 country
- SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsActive, not recruitingNCT06239480Phase 31 country
- National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)CompletedNCT055638311 country
- Topical Sirolimus in Cutaneous Lymphatic MalformationsCompletedNCT03972592Phase 21 country
- Bleomycin as an Effective and Curative Adjunct Therapy for LymphangiomaCompletedNCT069437031 country
- Indocyanine Green Lymphography in Management of Lingual Lymphatic MalformationCompletedNCT06755905Not applicable1 country
- Clinical Characteristics of Lymphatic MalformationsCompletedNCT062577191 country
- Lymphatic Function in Patients With Fontan Circulation: Effect of Physical TrainingCompletedNCT05934578Not applicable1 country
- Lymphatic Morphology of Fontan PatientsCompletedNCT041636531 country
- Sildenafil for the Treatment of Lymphatic MalformationsCompletedNCT02335242Phase 21 country
- First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene MutationsTerminatedNCT04409145Phase 1/21 country
- Vascular Anomaly Pathology and Genomics Biopsy StudyCompletedNCT04836884Not applicable1 country
- A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsWithdrawnNCT04994002Phase 11 country
- OK432 (Picibanil) in the Treatment of Lymphatic MalformationsCompletedNCT03427619Phase 21 country
- Lymphatic Function in Patients With a Fontan Circulation From BrazilCompletedNCT043945071 country
- Registry for Vascular Anomalies Associated With CoagulopathyCompletedNCT005768881 country
- Airway Vascular LesionsCompletedNCT00866827
- Lymphatic Function in Patients With a Fontan-Kreutzer CirculationStatus unknownNCT03379805
- A Study to Evaluate Sildenafil for the Treatment of Lymphatic MalformationsCompletedNCT01290484Phase 1/21 country
- Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic MalformationsCompletedNCT00010452Phase 2/31 country
- Selenium in the Treatment of Complicated Lymphatic MalformationsTerminatedNCT01212965Phase 11 country
- Diagnosis of Hemangiomas and Vascular MalformationsCompletedNCT00577213
- Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.CompletedNCT00261391Phase 11 country